224 related articles for article (PubMed ID: 26684608)
1. Isavuconazole: a role for the newest broad-spectrum triazole.
Slavin MA; Thursky KA
Lancet; 2016 Feb; 387(10020):726-8. PubMed ID: 26684608
[No Abstract] [Full Text] [Related]
2. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
[TBL] [Abstract][Full Text] [Related]
3. [NEW ANTIFUNGAL DRUGS FOR PREVENTION AND TREATMENT OF VISCERAL MYCOSES].
Pilmis B; Lortholary O; Lanternier FL
Rev Prat; 2015 Dec; 65(10):1334-9. PubMed ID: 26979038
[TBL] [Abstract][Full Text] [Related]
4. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial.
Horn D; Goff D; Khandelwal N; Spalding J; Azie N; Shi F; Franks B; Shorr AF
J Med Econ; 2016 Jul; 19(7):728-34. PubMed ID: 26960060
[TBL] [Abstract][Full Text] [Related]
5. Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
Ananda-Rajah MR; Kontoyiannis D
Future Microbiol; 2015; 10(5):693-708. PubMed ID: 26000646
[TBL] [Abstract][Full Text] [Related]
6. Isavuconazonium sulfate for the treatment of fungal infection.
Walker RC; Zeuli JD; Temesgen Z
Drugs Today (Barc); 2016 Jan; 52(1):7-16. PubMed ID: 26937491
[TBL] [Abstract][Full Text] [Related]
7. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.
Guinea J; Bouza E
Future Microbiol; 2008 Dec; 3(6):603-15. PubMed ID: 19072177
[TBL] [Abstract][Full Text] [Related]
8. Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.
Andes DR; Ghannoum MA; Mukherjee PK; Kovanda LL; Lu Q; Jones ME; Santerre Henriksen A; Lademacher C; Hope WW
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373791
[TBL] [Abstract][Full Text] [Related]
9. Use of isavuconazole in a patient with voriconazole-induced QTc prolongation.
Trang TP; Hanretty AM; Langelier C; Yang K
Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28434195
[TBL] [Abstract][Full Text] [Related]
10. Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.
Pfaller MA; Rhomberg PR; Castanheira M
Diagn Microbiol Infect Dis; 2018 Sep; 92(1):43-45. PubMed ID: 29735424
[TBL] [Abstract][Full Text] [Related]
11. The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.
Chitasombat MN; Kontoyiannis DP
Expert Opin Pharmacother; 2015; 16(10):1543-58. PubMed ID: 26100603
[TBL] [Abstract][Full Text] [Related]
12. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
Miceli MH; Kauffman CA
Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
[TBL] [Abstract][Full Text] [Related]
13. Isavuconazole as Salvage Therapy for Refractory Pediatric Coccidioidal Meningitis.
Naeem F; Laningham F; Kuzmic B; Clerkin P; McCarty J
Pediatr Infect Dis J; 2021 Mar; 40(3):e128-e131. PubMed ID: 33315746
[TBL] [Abstract][Full Text] [Related]
14. Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
Pettit NN; Carver PL
Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.
Gebremariam T; Alkhazraji S; Baldin C; Kovanda L; Wiederhold NP; Ibrahim AS
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264840
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.
Van Matre ET; Evans SL; Mueller SW; MacLaren R; Fish DN; Kiser TH
Ann Clin Microbiol Antimicrob; 2019 Mar; 18(1):13. PubMed ID: 30894179
[TBL] [Abstract][Full Text] [Related]
17. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
Cornely OA; Böhme A; Schmitt-Hoffmann A; Ullmann AJ
Antimicrob Agents Chemother; 2015 Apr; 59(4):2078-85. PubMed ID: 25624327
[TBL] [Abstract][Full Text] [Related]
18. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.
Thompson GR; Wiederhold NP
Mycopathologia; 2010 Nov; 170(5):291-313. PubMed ID: 20524153
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological profile of isavuconazole].
Azanza Perea JR; Sádaba Díaz de Rada B
Rev Iberoam Micol; 2018; 35(4):186-191. PubMed ID: 30477963
[TBL] [Abstract][Full Text] [Related]
20. Plain language summary: use of isavuconazole in Chinese patients with an invasive fungal disease.
Zhang J; Zhang Y; Wu D; Cao G; Hamed K; Desai A; Aram JA; Guo X; Fayyad R; Cornely OA
Future Microbiol; 2022 Oct; 17():1203-1206. PubMed ID: 35916057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
